A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Basal cell carcinoma (BCC) is the most frequent cancer in humans and results from constitutive activation of the Hedgehog pathway
1
. Several Smoothened inhibitors are used to treat Hedgehog-mediated malignancies, including BCC and medulloblastoma
2
. Vismodegib, a Smoothened inhibitor, leads to BCC shrinkage in the majority of patients...
Alternative Titles
Full title
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6295195
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6295195
Other Identifiers
ISSN
0028-0836
E-ISSN
1476-4687
DOI
10.1038/s41586-018-0603-3
